Please login to the form below

Not currently logged in
Email:
Password:

Lemtrada

This page shows the latest Lemtrada news and features for those working in and with pharma, biotech and healthcare.

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.

Latest news

  • Celebrating excellence Celebrating excellence

    The London-based agency picked up The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

  • Lucid behavioural change programmes recognised at PMEA Lucid behavioural change programmes recognised at PMEA

    The London-based agency picked The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

  • Sanofi forges $1.5bn cancer partnership with BioNTech Sanofi forges $1.5bn cancer partnership with BioNTech

    and Lemtrada (alemtuzumab) and subsidiary Genzyme's rare disease portfolio.

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • Sanofi persuades FDA to back its MS drug Lemtrada Sanofi persuades FDA to back its MS drug Lemtrada

    well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects". ... Lemtrada demonstrated superior efficacy over Rebif on annualised relapse rates in the two studies which were the basis for approval.”.

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics